Its team and advisors have been involved in over 75 regulatory submissions as of May 2024, with over 45 drugs approved as of April 2025. The company recently entered a first-of-its-kind collaboration with OpenAI and Sanofi to build specialized AI models and tools, such as 'Muse', designed to automate and optimize patient recruitment and trial design.
Cyborg Score Rationale
Formation Bio commands top-tier institutional backing (a16z, Sanofi, Sequoia), demonstrated execution (45+ approved drugs, 75+ regulatory submissions), and a defensible differentiation through proprietary AI-driven drug development. The June 2024 $372MM Series D validates scaled capital efficiency in a capital-intensive industry.
Top Insights
Addresses clinical trials bottleneck: Formation Bio tackles a $3.2 trillion pharmaceutical industry constrained by rising R&D costs and lengthy timelines
Strong institutional backing: Series D (June 2024) led by a16z with significant Sanofi participation signals confidence in the AI-pharma thesis
Proven regulatory track record: 45+ approved drugs and 75+ regulatory submissions demonstrate execution capabilities in highly regulated space
Integrated OpenAI partnership: Collaboration on AI tools for patient recruitment and trial design positions company at intersection of AI and biotech productivity
Named Competitors
Recursion Platform — AI-powered drug discovery and development
Exscientia Platform — AI-driven drug discovery and optimization
InSilico Medicine — AI platform for drug discovery and development
Recent Developments
(April 2025) Over 45 drugs approved across portfolio
(June 2024) Raised $372MM Series D financing led by Andreessen Horowitz with participation from Sanofi
Partnership with OpenAI and Sanofi on specialized AI models ('Muse') for clinical trial optimization
Open the full interactive Formation Bio report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.